C2i Genomics (סי2אי ג'נומיקס בע"מ)

South San Francisco, California, United States

C2i Genomics offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor's DNA. C2i's liquid biopsy is a tool for cancer tumor monitoring. It works by identifying subtle changes in genetic patterns across the entire tumor. Based on bioinformatics and artificial intelligence, it compares thousands of data points obtained from patients' periodic liquid biopsy blood tests to their own baseline of sequenced tumor tissue and whole-genome analysis. The unique pattern generated is converted to a cancer burden score, making cancer more predictable and manageable. The company's ultra-sensitive liquid biopsy assay allows physicians to monitor and improve their patients' treatment response and detect disease recurrence months and years before current monitoring methods are able to provide results.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out C2i Genomics (סי2אי ג'נומיקס בע"מ) on @MedStartr Today #CancerMonitoring #MetastaticCancer #Cancer #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/sRHRMNB-g9k

Get Involved in C2i Genomics (סי2אי ג'נומיקס בע"מ)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2019
Website: www.veracyte.com/

Disease Areas

Cancer Monitoring Metastatic Cancer

Technologies

Liquid BiopsyMolecular DiagnosticsDNA Sequencing

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of C2i Genomics (סי2אי ג'נומיקס בע"מ)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.